425 related articles for article (PubMed ID: 15723089)
1. Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis.
de Gouville AC; Boullay V; Krysa G; Pilot J; Brusq JM; Loriolle F; Gauthier JM; Papworth SA; Laroze A; Gellibert F; Huet S
Br J Pharmacol; 2005 May; 145(2):166-77. PubMed ID: 15723089
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor.
Gellibert F; de Gouville AC; Woolven J; Mathews N; Nguyen VL; Bertho-Ruault C; Patikis A; Grygielko ET; Laping NJ; Huet S
J Med Chem; 2006 Apr; 49(7):2210-21. PubMed ID: 16570917
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of ALK5 as a new approach to treat liver fibrotic diseases.
de Gouville AC; Huet S
Drug News Perspect; 2006 Mar; 19(2):85-90. PubMed ID: 16628263
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis.
Grygielko ET; Martin WM; Tweed C; Thornton P; Harling J; Brooks DP; Laping NJ
J Pharmacol Exp Ther; 2005 Jun; 313(3):943-51. PubMed ID: 15769863
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats.
Nakamura T; Sakata R; Ueno T; Sata M; Ueno H
Hepatology; 2000 Aug; 32(2):247-55. PubMed ID: 10915731
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542.
Laping NJ; Grygielko E; Mathur A; Butter S; Bomberger J; Tweed C; Martin W; Fornwald J; Lehr R; Harling J; Gaster L; Callahan JF; Olson BA
Mol Pharmacol; 2002 Jul; 62(1):58-64. PubMed ID: 12065755
[TBL] [Abstract][Full Text] [Related]
7. Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor.
Bonniaud P; Margetts PJ; Kolb M; Schroeder JA; Kapoun AM; Damm D; Murphy A; Chakravarty S; Dugar S; Higgins L; Protter AA; Gauldie J
Am J Respir Crit Care Med; 2005 Apr; 171(8):889-98. PubMed ID: 15563636
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis.
Higashiyama H; Yoshimoto D; Kaise T; Matsubara S; Fujiwara M; Kikkawa H; Asano S; Kinoshita M
Exp Mol Pathol; 2007 Aug; 83(1):39-46. PubMed ID: 17274978
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of ALK5 signaling induces physeal dysplasia in rats.
Frazier K; Thomas R; Scicchitano M; Mirabile R; Boyce R; Zimmerman D; Grygielko E; Nold J; DeGouville AC; Huet S; Laping N; Gellibert F
Toxicol Pathol; 2007 Feb; 35(2):284-95. PubMed ID: 17366323
[TBL] [Abstract][Full Text] [Related]
10. SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model.
Fu K; Corbley MJ; Sun L; Friedman JE; Shan F; Papadatos JL; Costa D; Lutterodt F; Sweigard H; Bowes S; Choi M; Boriack-Sjodin PA; Arduini RM; Sun D; Newman MN; Zhang X; Mead JN; Chuaqui CE; Cheung HK; Zhang X; Cornebise M; Carter MB; Josiah S; Singh J; Lee WC; Gill A; Ling LE
Arterioscler Thromb Vasc Biol; 2008 Apr; 28(4):665-71. PubMed ID: 18202322
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor-beta type 1 receptor (ALK5) and Smad proteins mediate TIMP-1 and collagen synthesis in experimental intestinal fibrosis.
Medina C; Santos-Martinez MJ; Santana A; Paz-Cabrera MC; Johnston MJ; Mourelle M; Salas A; Guarner F
J Pathol; 2011 Aug; 224(4):461-72. PubMed ID: 21465486
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of protective effect of phyllanthin against carbon tetrachloride-induced hepatotoxicity and experimental liver fibrosis in mice.
Krithika R; Jyothilakshmi V; Prashantha K; Verma RJ
Toxicol Mech Methods; 2015; 25(9):708-17. PubMed ID: 26337812
[TBL] [Abstract][Full Text] [Related]
13. IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy.
Moon JA; Kim HT; Cho IS; Sheen YY; Kim DK
Kidney Int; 2006 Oct; 70(7):1234-43. PubMed ID: 16929250
[TBL] [Abstract][Full Text] [Related]
14. Chinese medicine CGA formula ameliorates DMN-induced liver fibrosis in rats via inhibiting MMP2/9, TIMP1/2 and the TGF-β/Smad signaling pathways.
Li XM; Peng JH; Sun ZL; Tian HJ; Duan XH; Liu L; Ma X; Feng Q; Liu P; Hu YY
Acta Pharmacol Sin; 2016 Jun; 37(6):783-93. PubMed ID: 27133300
[TBL] [Abstract][Full Text] [Related]
15. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
Schniewind B; Groth S; Sebens Müerköster S; Sipos B; Schäfer H; Kalthoff H; Fändrich F; Ungefroren H
Oncogene; 2007 Jul; 26(33):4850-62. PubMed ID: 17297450
[TBL] [Abstract][Full Text] [Related]
16. Blockage of transforming growth factor beta receptors prevents progression of pig serum-induced rat liver fibrosis.
Jiang W; Yang CQ; Liu WB; Wang YQ; He BM; Wang JY
World J Gastroenterol; 2004 Jun; 10(11):1634-8. PubMed ID: 15162539
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts.
Mori Y; Ishida W; Bhattacharyya S; Li Y; Platanias LC; Varga J
Arthritis Rheum; 2004 Dec; 50(12):4008-21. PubMed ID: 15593186
[TBL] [Abstract][Full Text] [Related]
18. Enhanced effectivity of an ALK5-inhibitor after cell-specific delivery to hepatic stellate cells in mice with liver injury.
van Beuge MM; Prakash J; Lacombe M; Post E; Reker-Smit C; Beljaars L; Poelstra K
PLoS One; 2013; 8(2):e56442. PubMed ID: 23441194
[TBL] [Abstract][Full Text] [Related]
19. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors.
Goumans MJ; Valdimarsdottir G; Itoh S; Rosendahl A; Sideras P; ten Dijke P
EMBO J; 2002 Apr; 21(7):1743-53. PubMed ID: 11927558
[TBL] [Abstract][Full Text] [Related]
20. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.
Inman GJ; Nicolás FJ; Callahan JF; Harling JD; Gaster LM; Reith AD; Laping NJ; Hill CS
Mol Pharmacol; 2002 Jul; 62(1):65-74. PubMed ID: 12065756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
